Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs #ESMO17

da Salute H24 — 10 settembre 2017 alle 9:35


The ESMO Magnitude of Clinical Benefit Scale ( ESMO -MCBS) is a valid tool for grading orphan drugs, according to research presented at the ESMO 2017 Congress in Madrid. 

The ESMO -MCBS scales the clinical benefit that can be anticipated from new anti-cancer therapies for solid tumours. Continua »

AntonioCaperna

Scrivi un commento